Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from NovaBay Pharma ( (NBY) ).
On October 9, 2025, NovaBay Pharma entered into a Securities Purchase Agreement with R01 Fund LP and Framework Ventures IV L.P. to transfer shares of Series D and Series E Preferred Stock previously acquired by David Lazar. This transaction is contingent on stockholder approval at the company’s annual meeting on October 16, 2025, and upon completion, the purchasers are expected to collectively own approximately 90% of the outstanding common stock, significantly impacting the company’s ownership structure.
The most recent analyst rating on (NBY) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on NovaBay Pharma stock, see the NBY Stock Forecast page.
Spark’s Take on NBY Stock
According to Spark, TipRanks’ AI Analyst, NBY is a Neutral.
NovaBay Pharma’s overall stock score reflects significant financial challenges, with declining revenues and negative profit margins being the most impactful factors. While technical indicators show some bullish momentum, the valuation remains unattractive due to unprofitability. Positive corporate events, including a strategic shift and special dividend, provide some optimism for future prospects.
To see Spark’s full report on NBY stock, click here.
More about NovaBay Pharma
Average Trading Volume: 6,949,995
Technical Sentiment Signal: Sell
Current Market Cap: $7.57M
Learn more about NBY stock on TipRanks’ Stock Analysis page.